Beyond GPX4 inhibition: Unraveling the lethal mechanism of class III ferroptosis inducers
image: Proposed mechanisms of oxime-containing compound lethality. (A) A visual map of enzymes and metabolites in the mevalonate and cholesterol synthesis pathways that have been implicated in ferroptosis; (B) A simplified map of core lipid metabolic components essential to the execution of lipid-dependent necrosis induced by the oxime-containing lethal compounds CIL56 and tegavivint. CoA: coenzyme A; HMG-CoA: 3-hydroxy-3-methylglutaryl-coenzyme A; IPP: isopentenyl pyrophosphate; HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase; FPP:farnesyl pyrophosphate; GGPP: geranylgeranyl diphosphate; CoQ10: coenzyme Q10; SQS: squalene synthase; ER: endoplasmic reticulum; 7-DHC: 7-dehydrocholesterol; ACC1: acetyl-CoA carboxylase 1; TOFA: 5-(tetradeclyoxy)-2-furoic acid; 2-BP: 2-bromopalmitate; ZDHHCs: zinc finger DHHC domain-containing palmitoyl S-acyltransferases; TECR: trans-2,3-enoyl-CoA reductase.
Credit: © Scott J. Dixon*, et al. 2026. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
A new review article by Alby Joseph and Scott Dixon at Stanford University examines one of the most debated questions in ferroptosis research: how class III ferroptosis inducers trigger cell death and whether their lethal effects arise solely from GPX4 inhibition or involve broader mechanisms.
Published in the open-access journal Ferroptosis and Oxidative Stress, the article revisits the molecular basis of class III ferroptosis inducers and proposes a framework for understanding their unique mode of action.
Ferroptosis is an iron-dependent form of regulated cell death driven by the accumulation of lipid peroxides in cellular membranes. The process is normally restrained by antioxidant systems, most notably glutathione peroxidase 4 (GPX4), which detoxifies phospholipid hydroperoxides. Pharmacological compounds that disrupt these defenses can trigger ferroptotic cell death and have attracted significant interest as potential therapeutic agents against cancer and other diseases.
Ferroptosis inducers are commonly classified into several categories based on their mechanisms. While class I and class II compounds have been extensively characterized, the lethal mechanism of class III ferroptosis inducers remains less clearly defined.
In the article, the authors analyze current evidence surrounding class III ferroptosis inducers and discuss several key questions:
1. How do class III ferroptosis inducers differ from other ferroptosis-triggering agents?
Unlike compounds that directly inhibit GPX4 activity or deplete intracellular glutathione, class III inducers appear to act through distinct molecular routes that ultimately compromise cellular antioxidant defenses. Understanding these differences is essential for defining their place within the ferroptosis landscape.
2. Is GPX4 degradation the central lethal event?
Accumulating evidence suggests that many class III ferroptosis inducers promote GPX4 protein degradation rather than direct enzymatic inhibition. However, the precise contribution of GPX4 loss to cell death remains under active investigation. The authors discuss whether GPX4 degradation alone is sufficient to explain ferroptotic lethality or whether additional cellular changes are required.
3. What cellular pathways participate in the killing process?
The review highlights the potential involvement of protein quality-control systems, proteasomal pathways, autophagic processes, and stress-response networks. These mechanisms may cooperate with lipid peroxidation to determine ferroptotic sensitivity and execution.
4. Are all class III ferroptosis inducers mechanistically equivalent?
Although grouped into the same category, different compounds may engage distinct molecular targets and downstream pathways. The authors argue that a more refined mechanistic classification may be needed as the field advances.
5. What are the implications for therapeutic development?
A deeper understanding of class III ferroptosis inducers could facilitate the design of more selective ferroptosis-targeting therapies. By identifying the molecular determinants of sensitivity and resistance, researchers may improve strategies for exploiting ferroptosis in cancer treatment.
The authors conclude that deciphering the lethal mechanism of class III ferroptosis inducers is crucial not only for clarifying ferroptosis biology but also for guiding future drug development. As ferroptosis-based therapeutic approaches move closer to clinical translation, resolving these mechanistic questions will become increasingly important.